Exploring regulatory data sets of the Comirnaty vaccine - 12

Focussing on the demographics of the registration trial

We reported that provisional licensing for Comirnaty was granted by various regulatory bodies in late 2021.

The necessary evidence was based on Study C4951001: A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of SARS-COV-2 RNA Vaccine Candidates Against CO…